CD93. a transmembrane glycoprotein belonging to the C-type lectin family, plays critical roles in vascular development, immune regulation, and inflammation. It is expressed on endothelial cells, monocytes, and platelets, and interacts with ligands like IGFBP7 to mediate cell adhesion, angiogenesis, and phagocytosis. CD93 is implicated in pathological conditions such as tumor angiogenesis, atherosclerosis, and inflammatory diseases. Antibodies targeting CD93 have emerged as valuable tools for research and potential therapeutics. These antibodies are used to study CD93's expression patterns, signaling pathways (e.g., Hippo-YAP), and its role in endothelial permeability and leukocyte migration. In cancer research, anti-CD93 agents show promise in blocking tumor vascularization. Recent studies also explore their therapeutic potential in modulating immune responses and resolving chronic inflammation. However, the exact molecular mechanisms and clinical applicability of CD93 antibodies remain under active investigation.